Literature DB >> 15073253

PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis.

Marcus Henze1, Ashour Mohammed, Heinz P Schlemmer, Klaus K Herfarth, Simone Hoffner, Sabine Haufe, Walter Mier, Michael Eisenhut, Jürgen Debus, Uwe Haberkorn.   

Abstract

UNLABELLED: Differentiation between tumor progression and radiation necrosis is one of the most difficult tasks in oncologic neuroradiology. Functional imaging of tumor metabolism can help with this task, but the choice of tracer is still controversial. This prospective study following up irradiated low-grade astrocytoma (LGA) was, to our knowledge, the first receiver-operating-characteristic (ROC) analysis that intraindividually evaluated the diagnostic performance of the SPECT tracers 3-[(123)I]iodo-alpha-methyl-L-tyrosine (IMT) and (99m)Tc(I)-hexakis(2-methoxyisobutylisonitrile) (MIBI) and the PET tracer (18)F-FDG.
METHODS: We examined 17 patients, initially with histologically proven LGA and treated by stereotactic radiotherapy, who presented with new gadolinium-diethylenetriaminepentaacetic acid-enhancing lesions (n = 26) on MRI. At that time, MRI could not differentiate between progressive tumor and nonprogressive tumor. This MRI examination was closely followed by (18)F-FDG PET and by (99m)Tc-MIBI and (123)I-IMT SPECT. Lesions were classified as progressive tumor (n = 17) or nonprogressive tumor (n = 9) on the basis of prospective follow-up (through clinical examination, MRI, and proton MR spectroscopy) for 26.6 +/- 6.6 mo after PET or SPECT.
RESULTS: (123)I-IMT yielded the best ROC characteristics and was the most accurate for classification, with an area under the ROC curve (A(z)) of 0.991. The A(z) of (18)F-FDG (0.947) was not significantly lower than that of (123)I-IMT. The difference in the A(z) of (99m)Tc-MIBI (0.713) from the A(z) of the other tracers used in our study was highly significant (P </= 0.01). (99m)Tc-MIBI SPECT was of low accuracy and, especially, of poor sensitivity even at modest specificity values.
CONCLUSION: (123)I-IMT SPECT imaging of amino acid transport accurately detects tumor progression in patients with irradiated LGA. In contrast to (123)I-IMT, (18)F-FDG PET was slightly less accurate for classification, and (99m)Tc-MIBI SPECT was of limited value. Imaging of amino acid transport with (123)I-IMT is a valuable additional tool for the follow-up of LGA, allowing early, noninvasive differentiation of lesions with ambiguous morphology after irradiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073253

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Authors:  Mark E Mullins; Glenn D Barest; Pamela W Schaefer; Fred H Hochberg; R Gilberto Gonzalez; Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

3.  Pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT: does it have a place in predicting survival in patients with glioblastoma multiforme?

Authors:  Amr Amin; M Mustafa; E Abd El-Hadi; A Monier; A Badwey; E Saad
Journal:  J Neurooncol       Date:  2014-10-28       Impact factor: 4.130

Review 4.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

5.  Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results.

Authors:  Amr Amin; Hosna Moustafa; Ebaa Ahmed; Mohamed El-Toukhy
Journal:  J Neurooncol       Date:  2011-09-13       Impact factor: 4.130

6.  18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.

Authors:  Sellam Karunanithi; Punit Sharma; Abhishek Kumar; Bangkim Chandra Khangembam; Guru Pada Bandopadhyaya; Rakesh Kumar; Deepak Kumar Gupta; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-23       Impact factor: 9.236

Review 7.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Spyridon Voulgaris; Maria I Argyropoulou; Andreas D Fotopoulos
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

8.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

9.  Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence.

Authors:  Manuel Gómez-Río; Antonio Rodríguez-Fernández; Carlos Ramos-Font; Escarlata López-Ramírez; José Manuel Llamas-Elvira
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-03       Impact factor: 9.236

10.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.